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1. Introduction 
Diabetes mellitus is a heterogeneous group of chronic disorders of carbohydrate, lipid and 
protein metabolism characterized by high blood glucose levels due to relative or absolute 
deficiency of insulin (Eiselein et al., 2004). Hyperglycemia, the primary clinical 
manifestation of diabetes, is associated with the development of diabetic complications. 
Several studies have suggested that hyperglycemia accelerates the development of chronic 
complications via several mechanisms, including increased aldose reductase related polyol 
pathway flux, increased formation of advanced glycation end-products (AGEs), activation 
of protein kinase C isoforms, increased hexosamine pathway flux, and overproduction of 
reactive forms of oxygen (Brownlee, 2001). AGEs are a group of complex and heterogeneous 
compounds, including brown and fluorescent cross-linking substances (e.g., pentosidine), 
non-fluorescent cross-linking products (e.g., methylglyoxal lysine dimers), or non-
fluorescent, non-cross linking adducts (e.g., carboxymethyl lysine) (Dyer et al., 1991). 
Increasing evidence identifies AGE formation as the critical pathogenic link between 
hyperglycemia and long-term complications of diabetes: nephropathy, neuropathy, and 
retinopathy (Wada & Yagihashi, 2005). Therefore, another mode of diabetes treatment 
independent of blood glucose levels, inhibition of AGE formation, could be useful in the 
prevention or reduction of certain diabetic complications (Dong et al., 2010) in both main 
forms of the illness, Type 1 diabetes mellitus (T1D, insulin-dependent diabetes mellitus, 
IDDM) and Type 2 diabetes mellitus (T2D, noninsulin-dependent diabetes mellitus, 
NIDDM), and also in secondary forms related to gestation or other disorders. 
In 2010, WHO estimated that 285 million people were living with diabetes (corresponding to 
6.4% of the world's adult population). About 7 million people develop the disease each year 
and 3.9 million deaths were attributed to diabetes yearly (Shaw et al., 2010; Roglic & Unwin, 
2010). Current predictions estimate that the prevalence of diabetes will reach 438 million by 
2030 (corresponding to 7.8% of the adult population) and that 80% of prevalent cases will 
occur in the developing world (Roglic & Unwin, 2010). The increase is mainly driven by 
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changes in dietary habits and low levels of physical activity (Wild et al., 2004). In the poorest 
countries, diabetes is more common among the better-off, but economic development 
quickly reverses this trend so that people from lower socioeconomic groups are more 
affected by diabetes; consequences are worse among the poor in all countries (Whiting et al., 
2010, Blas & Sivasankara Kurup, 2010). Diabetes mellitus and specially diabetes with chronic 
complications belongs to the diseases requiring huge costs (Ettaro et al., 2004).  
Diabetes mellitus is a syndrome characterized by many symptoms most typical of which is 
hyperglycemia. T1D is 10% of all diabetes cases, but its prevalence is constantly increasing 
(Green et al., 2001). This type occurs most frequently around the age of 14 years and 
individuals affected by this type must be treated throughout life with insulin injections 
(Rossini et al., 2003). Disease is the result of inflammatory islet infiltration (insulitis) and 
selective destruction of insulin producing -cells (Atkinson and Eisenbarth, 2001). In general, 
diabetes being an autoimmune basis, T1D occurs frequently in individuals with other 
autoimmune diseases, especially intestinal or thyroid gland. It is strongly bound to major 
histocompatibility system (MHC), is dependent on T cells and can be modified by 
immunosuppression. When you start an autoimmune mechanism, exogenous factors play a 
role particularly of viral origin, but also antigens of the host cells based on molecular mimicry. 
These trigger tissue-specific immune response producing cross-reactive effector cells or 
antibodies that recognize self-proteins of  cells of the pancreas (Kukreja & Maclaren, 1999). 
Coxsackie B4 virus, for example, contains a sequence of 18 amino acids similar to enzyme 
glutamic acid decarboxylase (GAD) of pancreatic -cells (Kaufman et al., 1992). At the same 
time viruses can cause subtle damage to the -cells followed by autoimmune response against 
damaged -damaged cells with sequestrated virus antigen. Other studies have identified 
endogenous retroviral genomes in diabetic islets, but whether the virus initiates or is only a 
marker of the disease remains unclear (Benoist & Mathis, 1997). Regardless of the type of 
trigger are activated specific self reactive T cell clones against pancreatic -cells, which then 
infiltrate the islets of the pancreas. It is believed that these T cell clones belonging to the T 
helper 1 (Th1) subset. These Th1 cells produce characteristic cytokines, such as IFN and IL-2, 
which are considered as triggers of insulitis and destruction of -cells of the pancreas (Suarez-
Pinzon & Rabinovitch, 2001). Following the massive loss of pancreatic -cells develop severe 
deficiency of insulin resulting in hyperglycemia. This causes glycogenolysis in the liver, 
activate gluconeogenetic pathways and decreases cellular uptake of glucose in peripheral 
tissues (muscle and adipose). Extensive degradation of fats and oxidation of fatty acids leads 
to hyperlipidemia and ketosis. The essential symptoms include hyperglycemia, polyuria due 
to osmotic diuresis, thirst due to hyperosmolar state, weight loss due to depletion of fat 
reserves and negative nitrogen balance, neurotoxicity due to hyperglycemia and ketoacidosis 
(Eiselein et al., 2004). If patients are not treated die due to circulatory collapse and coma. When 
initiating therapy by exogenous insulin, but are frequent hyperglycemia, develop micro- and 
macroangiopathies. Therefore, in diabetic patients is increased risk for coronary heart disease, 
stroke, gangrene of the lower limbs, chronic kidney disease, blindness and visual disturbances, 
and autonomic and peripheral neuropathy. These problems reduce life expectancy by up to 
25% (Williams & Pickup, 2004) and the most common causes of death are diseases of heart and 
kidney. 
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In addition to people diabetes mellitus are quite often found in animals living with man 
(dog, cat), pets (or livestock) and laboratory animals (Malaisse & Sener, 2008). 
For eliminate ethical and logistic problems in the study of T1D in connection with the 
heterogeneity of outbreed human populations, have been developed so many animal 
models of induced and spontaneous diabetes with the possibility of more frequent 
sampling, biopsy and autopsy samples. In these models it is possible to breeding at a 
controlled heredity and study of various environmental factors in relatively large and 
uniform populations. Animal models have a special status in the study of pathogenesis of 
chronic complications of diabetes, which are considered the following mechanisms: (1) 
non-enzymatic glycosylation, (2) intracellular hyperglycemia with associated disturbances 
in the polyol pathway, (3) activation of protein kinase C (PKC) and (4) increased 
hexosamine pathway flux (Eiselein et al., 2004). Non-enzymatic glycosylation lead to 
irreversible formation of advanced glycation end products (AGEs) through the Maillard 
reaction, and this is probably the best studied pathogenetic factor of diabetic 
complications. Pathological effects of AGEs are induced by impaired function of 
glycosylated products and by activation of AGE receptors on endothelial cells, monocytes, 
macrophages, lymphocytes and mesenchymal cells. Increased risk of heart diseases in 
diabetics is mainly attributed to the formation of AGEs (Eiselein et al., 2004). 
Glycosylation of collagen type IV in basement membranes of blood vessels leads to cross-
links between interstitial proteins and lipoproteins, e.g., LDL. (Vlassara, 1996). LDL can be 
glycosylated and subsequently oxidized (Bucala et al., 1993). Modified LDL can then be 
bound to receptors of macrophages (CD36). The resulting foam cell formation and 
development of the fatty streak in the sub-endothelial space is the beginning of the 
atherosclerotic process (Ohgami et al., 2001). Since in diabetics the levels of AGEs of 
apoprotein B and phospholipids are several times higher as compared to nondiabetics, 
diabetics have a three- to four-fold higher risk of cardiovascular diseases (Bucala et al., 
1994) and it is expected that non-enzymatic glycation is responsible also for vascular 
occlusions (Peppa et al., 2004). Other studies have attributed the importance of AGEs in 
hypertension, kidney pathology and erectile dysfunction in diabetics. These injuries are 
caused by AGEs present in the vascular matrix, where it inhibits the vasodilatory effect of 
EDRF (NO) and increased expression of endothelin-1, a potent vasoconstrictor 
(Quehenberger et al., 2000). Many of the effects of AGEs are dependent on the receptor. 
The best characterized receptor of AGEs is the receptor for advanced glycation end 
products (RAGE), which is a member of the immunoglobulin superfamily of cell 
membrane molecules (Stern et al., 2002). Studies in rodent models demonstrated that 
blocking RAGE can inhibit vascular hyperpermeability and reduced development of 
atherosclerotic lesion (Wendt et al., 2002). These results suggest that AGE-RAGE system 
may be a promising target for prophylaxis and treatment of late complications of diabetes 
mellitus. Hyperglycemia can cause various damages by changing polyol pathway,   
diacylglycerol-PKC pathway is important for develop of micro- and macro-angiopathy, 
and finally hexosamine biosynthetic pathway is also involved in the development of 
diabetic vascular complications (Eiselein et al., 2004).  
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In the study of T1D is primarily used two species of laboratory animals, rat and mouse (von 
Herrath and Nepom, 2009). The most commonly used model is non-obese diabetic (NOD) 
mouse (Serreze and Leiter, 2001). Many data in the literature explains the genetics and 
immunology of these animals and they were identified by at least 27 genetic loci and many 
immunological defects (Serreze and Leiter, 2001). Their disadvantages as a model consisted of 
two facts. Firstly, for this model in addition to immunosuppression also other 
immunomodulatory interventions showed a preventive effect on diabetes (Atkinson & Leiter, 
1999), in contrast, these were ineffective in humans (Skyler et al., 2002). Second, because some 
of the negative factors of environment, particularly viral infections (Leiter, 1998) reduced the 
frequency of diabetes and often act preventively in mice (Atkinson & Leiter, 1999), while in 
humans viruses are known triggers. Although the original NOD mice and congenic strains 
derived from them provide valuable information and is necessary to keep in mind that they 
are not completely appropriate alternative to studying human T1D (Greiner et al., 2001). Rats 
provide another model. Such are BB rats (Mordes et al., 2001), a widely studied model 
susceptible to autoimmune destruction of pancreatic -cells. In some experiments also 
nonmammal models can be exploited due they easy handling and low economic costs. 
Use of animal models in diabetes research has a long tradition. Our aim was to present an 
overview of animal models used in research of diabetes mellitus and highlight some 
technological and scientific problems associated with interpretation of carrying out these 
experiments in accordance with current European legislation on animal protection and 
exploitation of animals for experimental purposes (Ništiar et al., 2006). It is based on 
detailed analysis of the literature, using well-known databases such as MEDLINE, 
HighWire Press, PubMed and basic book, "Animal Models of Diabetes: A Primer" (Sima 
& Shafrir, 2000). 
Already in 1890, von Mehring and Minkowski induced in dogs by removing the pancreas 
acute diabetes mellitus (Minkowski, 1989). In addition to partial and the total 
pancreatectomy, there are also non-surgical methods to induce hyperglycemia. There are 
five groups of diabetogenic substances: chemical and biological agents, potentiators, 
peptides and steroids (van der Werf et al., 2007). Among the animal models include in 
particular rodents, which are especially suitable for their low cost, short generation time, 
inherited forms of obesity and hyperglycemia. There are known animal models to study 
T1D also T2D (Rees & Alcolado, 2005; Yang & Santamaria, 2006). Animals with spontaneous 
T1D have been drawn by inbreed breeds in different laboratories. In contrast, animal models 
of T2D are very heterogeneous. This includes not only animals with single-gene mutation, 
but also other types with insulin resistant syndrome and impaired pancreatic -cells 
(Matteucci & Giampietro, 2008).  
More recently techniques using methods of molecular biology have produced genetically 
modified mouse models, including knockout and transgenic animals. Knockout animals 
have been defective gene in embryonic stem cells. In transgenic animals modified gene is 
incorporated into the pronucleus of zygote and then randomly into the genome of the 
animal and is transferred to the offspring.  
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Diabetic animal models undoubtedly have enormous benefit in clarifying the effect of 
insulin and insulin therapy. They also have some shortcomings, particularly when 
extrapolating results to humans and diabetic complications in humans (Tesch & Nikolic-
Paterson, 2006) as well as some results may be misleading in the study of T1D prevention by 
using of model rodents (Leiter & von Herrath, 2004). It is claimed that the rodents in this 
area do not adequately reflect the situation in humans (Yang & Santamaria, 2006). 
Accordingly, these models and experiments will be necessary to standardize especially for 
prevention studies. Reliable results about the differences of pharmaceutical efficiency or 
survival of animals, delays and onset of disease, temporal relation of events require a very 
clear interpretation and repeatability of the experiment as well as the establishment of 
appropriate databases.  
2. Basic considerations 
Already in the Helsinki Declaration of the World Medical Association, 1964 (since been 
revised and amended) Rule 12 says that "to be secured by appropriate conditions, 
environment and care of experimental animals included in the experiment." The protection 
and welfare (only vertebrates) used for experimental purposes is regulated by: Council 
Directive 86/609/EEC, Directive 2003/65/EC, Council Decision 1999/575/EC and Council Decision 
2003/584/EC. While there are considerable differences in the application of these measures in 
own legislation of individual countries. 23rd January 2006 the European Commission 
presented a modified and a new Action Plan for to ensure the welfare of animals in the 
future to a much higher level in all European Union member countries. 
In 1959, zoologist William Russell and microbiologist Rex Burch presented a proposal for 
research on the three R: replacement, reduction and refinement (Russell & Burch, 1959). As 
the replacement is considered using any technique with insensitive material that replaces 
the use of susceptible live vertebrate animals. For the relative replacement is considered 
when animals are used only in certain parts of experiment thereby minimize distress during 
the whole experiment. Absolute replacement is if susceptible live animals are not used at 
any stage of the experiment. Organ and tissue cultures represent a transition between 
absolute and relative replacement. Reduction is one of the methods that allow researchers to 
reduce the number of animals used for research without reducing the statistical significance. 
In terms of statistical significance is extremely important to determine the number of 
animals needed for certain types of biomedical research (Dell et al., 2002). The significance 
of the test must be such as to enable to assess the clinical significance of the monitored 
phenomenon. Although the difference is less, we can be made certain conclusions (trends) 
without the need to increase the number of animals. This is necessary to meet two basic 
requirements, and that the differences have a normal distribution to determine the standard 
deviation.  
Refinement is provided by better care of the animals. Fourth R, responsibility aims at 
increasing the accountability of scientists using animals in experiments (Bark, 1995). This 
area is in the forefront in recent years. 
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Report A2005 submitted consensus on animal experiments in the present. It also 
submitted a proposal for the basic procedures and compliance with conditions of four R 
(Perry, 2007). 
Regarding diabetes mellitus is necessary to admit that the conditions regarding the 
extrapolation of the results of animal experiments to conditions in humans are not clearly 
clarified. There are neither clearly intended technical conditions for carrying animal 
experiments for obtaining scientific knowledge. If the technological of the performance of 
experiments conditions are not sufficiently clarified one cannot even assume that their moral 
and ethical aspects are in order. From that aspect, it is clear only that the animals were 
subjected to experiments at the lowest discomfort (Rees & Alcolado, 2005).     
Animal models are possible principally to divide into five groups (Hau, 2008):  
1. induced (experimental) models; 
2. spontaneous (genetic mutant) models;  
3. genetically modified models (transgenic animals); 
4. negative models (strain of animals in whom the studied disease does not occur) and  
5. orphan models, describing the malfunctions that occur in the model animal, but do not 
occur in humans (e.g., Marek's disease, bovine spongiform encephalopathy, etc.). 
Induced (experimental) models are represented by animals in which a modeled 
phenomenon as diabetes was induced by certain agents, e.g., chemical (alloxan, 
streptozotocin, cow's milk), viruses (encephalomyocarditis virus) or pancreatectomy.  
The use of animals for experimental purposes is always encountered negative response from 
the public, especially on the basis of ethical and religious reasons. These efforts led to the 
gradual formation of legislation towards the protection of animals used for experimental 
purposes. Nevertheless these experiments have contributed significantly to the current 
scientific knowledge of human biology, physiology, endocrinology and pharmacology (Loew, 
1996). Outputs from these experiments were often not extrapolated to humans and it has also 
led to efforts to reduce them and to legislation guidance and control. On the other hand it 
should be noted that these very often contribute to a better understanding of many biological 
phenomena. Science on laboratory animals can be defined as a professional field focused on 
issues of scientific, ethical and lawful use of animals for biomedical research, i.e. 
interdisciplinary science involving biological and pathobiological details for optimal scientific 
use of animals as models for humans or other species. In general it deals with the quality of 
animals as susceptible objects in biomedical research. It includes comparative biology of 
laboratory animals, aspects of the breeding and reproduction (cross), welfare, economy of 
farming, anesthesia, euthanasia1, and experimental procedures. The basic precondition for the 
use of animals for experimental purposes is a competence of researcher, including a solid 
knowledge about the biological needs, care and handling of animals.  
                                                                 
1 “Euthanasia” in association with the termination of life in animal experiment is a widely used term which on the 
other side is a mistake.  
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If the use of animals for experimental purposes is an essential condition a similarity of the 
animal with modeled objects in the light of studied phenomenon, i.e. concept the analogy 
of animal models. If the analogy is closer the possibility of extrapolation of results is much 
more reliable. Extrapolation is used to express to what extent can be used the results from 
animal experiments to humans (how are applicable to humans). In the analysis from big 
multinational pharmaceutical companies in 150 compounds were monitored compliance 
(concordance) between animal models and human subjects (Olson et al., 2000). 
Concordance determining the toxicity of the substances to humans if were tested in 
rodents and non-rodents was 71%, when used only non-rodents 63% and if used only 
rodents 43%. High concordances are detected in the cardiovascular toxicity (80%), 
hematological toxicity (91%) and gastrointestinal toxicity (85%). Low concordances are in 
the neurological manifestations. Despite the high concordances in animal experiments are 
often reports of damages in humans by preparations of certain pharmaceutical companies. 
E.g., penicillin is fatal for the guinea pig, but it is well tolerated by humans, aspirin is 
teratogenic for cats, dogs, guinea pigs, rats, mice and monkeys, but not teratogenic for 
pregnant women, despite their frequent use (Mann, 1984). Thalidomide causing 
malformations in 10 000 children did not cause birth defects in rats (Koppányi & Avery, 
1966) nor in many other species (Miller & Strömland, 1999). The close phylogenetic or 
morphological similarity is not crucial for the biochemical mechanisms and physiological 
responses, although in many cases this is so (Beynen & Hau, 2001). A very important 
difference between experimental animals and human populations is their genetic 
variability. Experimental animals are genetically almost identical in contrast to man 
exhibiting great variability. It is therefore possible to lay down precise rules for 
extrapolation of results from one species to another species, although in the literature 
have been made to certain procedures (Calabrese, 1991). Under the extrapolation is 
necessary to bear in mind certain mathematically expressed values, although it often looks 
precisely from this aspect, e.g., in determining the toxicity of certain substances or to 
determine of pharmacologically effective doses of drugs. In our opinion, fundamental 
importance is the rather in detection of toxic or therapeutic efficacy of substances. For 
specific determination of toxic or biologically effective dose, they should be taken in 
extrapolating only as a possible benchmark. Therefore, for any type of research should be 
borne in mind that the use of animal model does not attempt to extrapolate the main 
objective of the immediate outcome of the man, but looking for an answer to questions of 
researcher. While examining the need of experiments on animals it is first necessary to 
determine whether the experiment gave relevant answer to the experimenter, and 
whether the answer to the question enriches the current knowledge about the studied 
phenomenon. With this reason should be hypothesis (question) subjected to analysis 
before the experiment (approval of animal experiments, ethics committees, input 
opponency), and after publishing the results (answers to questions) and by the public 
opinion (responses).  
Selection of animal species for the experimental purpose must be based on the greatest 
similarity between model object and modeling object, therefore the found results showed 
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the strong concordance and therefore extrapolation was valid. It is well known that the 
metabolic rate in young and small animals is much higher than in large and old animals, 
because body size is the one of the key indicators and benchmarks for extrapolation, and 
precisely on the basis that have been submitted to the methods of extrapolation for the 
calculation of effective or toxic doses of various compounds (Hau & Poulsen, 1988).  
3. Animal models for the study of diabetes mellitus 
Recently almost 140 years passed from the excellent experiments of Mehring and 
Minkowski with pancreatectomized dogs. There have been many experiments with this 
model on rabbits and dogs when Banting and Best came to experiment, which led to the 
beginning of the isolation and purification of insulin (Bliss, 1982). Dog Marjorie, who was 
first treated with exogenous insulin, is probably one of the most famous experimental 
animal in the history, comparable only with Dolly the sheep from genetic studies at the end 
of the last century. The early experimental models of diabetes were focused on 
pancreatectomized (partial or total) animals. Selection of species was more or less 
spontaneous. Usually used by small animals (mostly rats and mice), both because of 
handling or space needs and the affordable price. These experiments have often been 
questioned that the extrapolation to humans is appropriate from experiments on larger 
animals such as cats, dogs, pigs and primates (McNamara et al., 2009). 
Among the non-surgical method inducing hyperglycemia after pancreatic damage with 
toxic substances, the most famous are streptozotocin (Junod et al., 1969) and alloxan (Lenzen 
& Panten, 1988; Lenzen, 2008). Surgical and non-surgical methods are a good model for 
studying the consequences of chronic hyperglycemia and the development of diabetic 
complications (Salgado et al., 2001). Using female animals it is also possible to study the 
effects of hyperglycemia to the offspring (Caluwaerts et al., 2003). Problems related to 
control of hyperglycemia, application of insulin or oral antidiabetic drugs require further 
improvements of experiments (Herrera et al., 1985). It should be noted that euglycemia 
cannot be reached in pancreatectomized animals (Harder et al., 2003). In pancreatectomized 
animals also transplantation of Langerhans' islet cells was studied. Islets cells can be 
transplanted without capsules or in capsules that protect them from rejection (Lanza et al., 
1999), either subcutaneously (Wang et al., 2011), or under the kidney capsule (Korec, 1991, 
Carlsson et al., 2000) or via the portal vein to the liver (Trimble et al., 1980). Transplanted 
animals must receive antirejection therapy (Kobayashi et al., 2008). Like in humans is a key 
event in many successful interventions should be carried out (how many animals to be 
used) so that we can draw on the basis of their results, conclusions appropriate for 
transplantation programs. 
Rodents are commonly used models for testing the new pharmacologically active 
substances not only in the context of transplantation (immunosuppressives), but also with 
regard to therapy or prevention of human diseases. Rats and mice are commonly used in 
safety and effectiveness testing of new orally active compounds. These experiments also led 
to unexpected findings about how the PPAR  agonists may have a protective effect on the 
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-cells (Bonora et al., 2008). Similarly, in such experiments were also identified the effects of 
insulin analogues for the development of tumors (Sandow, 2009).  
Experimental animals used to study of diabetes mellitus can be essentially classified into 
several groups (Shafrir, 2003): 
1. Animals with chemically induced destruction of pancreatic -cells: 
a. Alloxan model  
b. Streptozotocin (single dose) 
c. Streptozotocín (more subdiabetogenic doses). 
2. Animals with spontaneous autoimmune diabetes: 
a. BB rats 
b. NOD mice 
c. Akita mice 
d. LETL rats 
e. Torii rats 
f. LEW.1AR1/ZTM. 
3. Genetically altered animals (transgenic models) with various form of diabetes 
4. Insulin resistant mutants of rodents with potent diabetogenity: 
a. C57BKs db mice (leprdb) 
b. C57BL6J ob mice (lepob) 
c. Yellow Av a Avy mice 
d. KK mice 
e. NZO mice 
f. Zucker fa rats (leprfa) and BB/Wor rats 
g. Zdf/Drt-fa rats 
h. Wistar-Kyoto diabetic/fatty rats 
i. Obese (corpulent, cp) rats of strains SHR/N-cp, LA/N-cp, SHHF/Mcc-cp 
and JCR.LA-cp. 
5. Rodents with spontaneous diabetes of various etiology: 
a. NON mice 
b. WBN/Kob rats 
c. ESS rats 
d. BHE/Cdb rats 
e. OLETF rats 
f. NSY mice 
g. Koletzky (SHROB) rats (faK) 
h. Hypertriglyceridemic (HTG) rats 
6. Rodents by overfeed induced diabetogenity: 
a. Psammomys obesus (sand rats, gerbil) 
b. Acromys cahirinus (spiny mice) 
c. C57BL/6J mice 
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Diabetic rodents obtained by selective crossbreeding from normal strains: 
d. GK (Goto-Kakizaki) rats 
e. Cohen diabetic rats (induced by diabetogenic diet rich in sucrose and poor in copper). 
7. Diabetic non-rodents: 
a. Primates  
b. Pigs  
c. Dogs 
d. Cats. 
3.1. Models of spontaneous type 1 diabetes mellitus (T1D) 
The most known models of spontaneous T1D include NOD (non-obese diabetic) mice and 
BB (BioBreeding) rats, having a many common features with human T1D (von Herrath 
& Nepom, 2009). In addition to these we include here LETL (Long Evans Tokushima Leans) 
and KDP (Komeda diabetes prone) rats, LEW congenic rats, New Zealand white rabbits, 
Keeshond dogs (long haired dog of Dutch race), Chinese hamster and Celebes black apes. It 
should be noted that these animals are kept as inbred in laboratory conditions for many 
generations and gradually selected to hyperglycemia.  
An excellent overview and classification of animal models of T1D is in von Herrath 
& Nepom (2009): 
 Spontaneous or genetically modified diabetic animals: 
 Non-obese: 
 NOD mice 
 Akita mice 
 BB rats 
 LETL (Long-Evans Tokushima Lean) rats 
 KDP (Komeda diabetes prone) rats 
 LEW.1AR1/Ztm-iddm rats  
 Monkeys 
 Keeshond dogs 
 Some races of cats (feline models). 
 Chemically induced diabetic animals: 
 Non-obese: 
 Single dose of ALX, respectively, more low doses of STZ 
 Vacor (rodenticide, which acts as an antagonist of B vitamins, particularly 
nicotinamide), dithizone, dehydroascorbic acid, pentamidine and 8-
hydroxyquinoline. 
 Surgically prepared diabetic animals: 
 Non-obese: 
 Totally pancreatectomized animals, e.g., dogs, primates, pigs and rats. 
 Virus-induced models. 
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3.2. Models of spontaneous type 2 diabetes mellitus (T2D) and monogenic forms 
of diabetes 
T2D is a heterogeneous group of disorders characterized by insulin resistance and impaired 
insulin secretion, defined by elevated fasting glycemia and hyperglycemia after load of 
glucose. Some newer subtypes of diabetes are based on single-gene defect, called MODY 
(Maturity Onset Diabetes of the Young) syndromes (Vaxillaire & Froguel, 2008), syndromes 
with severe insulin resistance (Semple et al., 2011) and a mitochondrial diabetes (Berdanier, 
2007). In most patients, diabetes is caused by several genetic and environmental factors and 
disease development in all leads to chronic complications.  
Animal models of T2D are complex and heterogeneous as in humans (Kaplan & Wagner, 
2006). Advances in the interpretation of the problem coming from various sources and 
models (ob/ob mice – monogenic model of obesity with leptin deficiency, db/db mice – 
monogenic model of obesity with leptin resistance, Zucker fa/fa rats – monogenic model of 
obesity with resistance to leptin; Goto Kakizaki rats, KK mice, NSY mice, OLETF rats, Israeli 
sand [desert] rats, streptozotocin-treated rats receiving fat diet, CBA/Ca mice, New Zealand 
obese mouse). In some animals, is dominated insulin resistance, compared to other it is 
damage of pancreatic -cells (Cefalu, 2006). Animals with glucose intolerance and 
phenotypically more obese with dyslipidemia and hypertension are a good model of human 
T2DM. Similar to NOD mice and BB rats for T1D, selective inbreeding increases the 
spontaneous incidence of T2D. Most of the studies come from monogenic models of ob/ob, 
db/db, fa/fa and agouti strains (Franconi et al., 2008). 
Obesity and subsequent insulin resistance are the main triggers of T2D in humans. Due 
to strong similarities with humans animal models must be obese. Some strains maintain 
euglycemic status with a strong and sustained compensatory response to -cells, leading 
to insulin resistance and hyperinsulinemia. Similarly, ob/ob mice and fa/fa rats are a good 
example of this phenomenon. For others, such as db/db mice and Psammomys obesus 
which were rapidly develops hyperglycemia and therefore -cells are not able to 
maintain high levels of insulin. The study of these different animal models may be 
helpful in explaining why some people with morbid obesity never develop T2D while in 
others hyperglycemia is already at relatively mild insulin resistance and obesity 
(Tirabassi et al., 2004). 
These models have also contributed significantly to the study of obesity (Srinivasan 
& Ramarao, 2007). In 1994, Friedman with coworkers cloned ob/ob mice with a mutant gene 
for severe obesity (Zhang et al., 1994). Normal ob gene encodes a protein secreted by 
adipocytes and called leptin. In db/db mice and fa/fa rats was found mutations in the gene for 
the hypothalamic leptin receptor (Lee et al., 1996). 
Recent classification of animals for modeling of T2D: 
 Spontaneous or genetically modified diabetic animals: 
 Obese: 
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 ob/ob mice 
 db/db mice 
 KK (Kuo Kondo) mice 
 KK/Ay (yellow obese) mice 
 NZO mice 
 NONcNZO10 mice 
 TSOD (Tsumura Suzuki obese diabetic) mice 
 M16 mice 
 Nagoya-Shibata-Yasuda (NSY) mice 
 Zucker fatty rats 
 ZDF (Zucker diabetic fatty) rats 
 Obese-hyperglycemic Wistar Kyoto rats 
 SHR/N-cp rats 
 SHHF/Mcc-cp rats 
 JCR/LA-cp rats 
 OLETF rats 
 eSS rats 
 BHE/Cdb rats 
 Koletzky (SHROB) rats 
 Yucatan miniature pigs 
 Sinclair miniature pigs 
 Göttingen miniature pigs 
 Ossabaw pigs 
 Familial hypercholesterolinemic pigs (FHP) 
 Obese rhesus monkeys 
 Macaca fascicularis 
 Macaca radiata  
 Papo anobis. 
 Non-obese: 
 WBN/Kob rats 
 Goto Kakizaki (GK) rats 
 Hypertriglyceridemic (HTG) rats 
 Torii rats (SDT, spontaneously diabetic Torii) 
 Torii non-obese mice C57BL/6 
 ALS/Lt mice 
 Non-obese mutant C57BL/6 (Akita) mice. 
 With diet/nutrition induced diabetic animals: 
 Cohen diabetic rats 
 Psammomys obesus  
 Acomys cahirinus 
 Ctenomys talarum (tuco tuco) 
 Guinea pigs (Cricetulus griseus) 
 C57/BL 6J mice 
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 Macaca mullata 
 Dogs 
 Cats 
 Chinese Guizhou mini-pigs. 
 Chemically induced diabetic animals: 
 Obese: 
 GTG (gold thioglucose)–treated obese mice 
 Yorkshire and with Yorkshire crossbred strains of pigs (STZ-induced 
diabetes). 
 Non-obese: 
 Single low dose of ALX or single dose of STZ to adult rats, mice and etc. 
 Neonatal STZ-treated rats. 
 Surgically prepared diabetic animals: 
 Obese: 
 VMH (ventromedial hypothalamus)–damaged dietetically obese diabetic 
rats. 
 Non-obese: 
 partially pancreatectomized animals, e.g., dogs, primates, pigs and rats. 
 Transgenic/knockout diabetic animals: 
 Obese: 
 3 receptor knockout mice 
 UCP1 knockout mice. 
 Non-obese: 
 transgenic or knockout mice in genes for insulin, insulin receptor and their 
components in the direction of insulin signaling, i.e., IRS-1, IRS-2, GLUT-4, 
PTP-1B and other 
 PPAR- tissue specific knockout mice 
 Glukokinase or GLUT-2 gene knockout mice 
 HIP rats (rats with overexpession of human islet amyloid polypeptide). 
3.3. Models of spontaneous type 2 diabetes mellitus – Advantages and 
disadvatages 
In view of advantages and disadvantages of different models of T2D animal models, we can 
say that: 
 Spontaneous or genetically modified diabetic animals have: 
 Advantages: 
 Development of T2D is a spontaneous and provides genetic factors. In animals 
developed the similar features as in human T2D. 
 Animal models are mostly inbred in which is homogeneous genetic 
background and environmental factors are well controllable. 
 Variability of the results is minimal and requires a small number of animals. 
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 Disadvantages: 
 They are highly inbred, homogeneous, and often with monogenic inheritance 
therefore development of diabetes is strongly genetically determined versus 
heterogeneity in humans. 
 Limited life span and the time dimension of diabetes study. 
 In animals with brittle pancreas (db/db, ZDF rats, P. obesus, and other) is high 
mortality caused by ketosis and therefore need insulin treatment to prolong 
their life. 
 Require more sophisticated forms of breeding purposes and care. 
 With diet/nutrition induced diabetic animals: 
 Advantages: 
 The development of diabetes associated with obesity is the result of overfeed, 
as it is also in diabetes in human populations.  
 Toxicity of chemical (diabetogenic) compounds to other vital organs and 
tissues can be eliminated. 
 Disadvantages: 
 Animal models often require long periods of dietary treatment.  
 Not too significant hyperglycemia are after a simple dietary treatment in 
genetically normal animals and are therefore unsuitable for studying 
antidiabetogenic substances by determining of blood glucose. 
 Chemically induced diabetic animals: 
 Advantages: 
 Selective loss of -cells of the pancreas (alloxan/STZ), while maintaining of 
intact  - and -cells. 
 Residual insulin secretion allows animals to live without insulin therapy a 
relative long time. 
 Ketosis and subsequent mortality is relatively low. 
 They are cheaper and easier to maintain. 
 Disadvantages: 
 Hyperglycemia develops primarily as a result of direct cytotoxic effects on -
cells and subsequent insulin deficiency and not as a result of insulin 
resistance. 
 Chemically induced diabetes is less stable and often occurs spontaneously 
regeneration of pancreatic -cell, which is a disadvantage of long-term 
studies. 
 In chemically induced diabetes can be toxic substance damaged other 
molecular structures, and may result to the general toxic effects.  
 Variability of results with regard of hyperglycemia is very high.  
 Surgically prepared diabetic animals: 
 Advantages: 
 Eliminates the cytotoxic effect of chemical diabetogenic substances to other 
organs and tissues. 
 Strongly resembles regarding reduction of -cell mass to human T2D. 
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 Disadvantages: 
 Technical complexity and cumbersome, postoperative procedures. 
 The occurrence of certain digestive problems (as result of excision of the 
exocrine pancreas, amylase deficiency, etc.). 
 Removal of -cells (glucagon producing) together with -cells leads to 
problems in regulation of hypoglycemic events. 
 Mortality is relatively high.  
 Transgenic/knockout diabetic animals: 
 Advantages: 
 The effect of a single gene or their mutations on diabetes can be studied in vivo.  
 Greatly facilitate the resolution of the genetic complexity of T2D. 
 Disadvantages: 
 Highly sophisticated and expensive procedures for production and breeding. 
 Very expensive for routine screening tests. 
Spontaneous T2D diabetic animals are normally obtained from animals with mutations in 
one or more genes that are transmitted from generation to generation (e.g., ob/ob, db/db mice) 
or the selection from non-diabetic outbred animals selectively crosses over several 
generations (e.g., GK rats, TSOD mice). These animals have congenital diabetes with the 
monogenic or polygenic defects. Metabolic peculiarities may be due to a single gene defect 
(monogenic) with a dominant phenotype (e.g., yellow obese KK/Ay mice) and the recessive 
phenotype (diabetic db/db mice, Zucker fatty rats) or may have polygenic origin (i.e. KK 
mice, NZO mouse) (Aerts & Van Assche, 2006). T2D in humans is the result of interaction 
of different environmental factors and many genes which under certain conditions may 
manifest as diabetes with very contrasting symptomatology (e.g., MODY), single-gene 
defects with clinically overt diabetes are rare. Therefore, animals with polygenic defects are 
more objective for a modeling study of T2D in humans (Lofty et al., 2011). 
4. Problems of evaluation and interpretation of the results from animal 
experiments 
Long-term fluctuations in blood glucose levels can lead to loss of consciousness in animals. Both 
hyperglycemia and hypoglycemia can lead to diabetic coma, which is characterized by 
disorientation and convulsions. Diabetic coma is a life-threatening event. Without therapy of 
diabetic rats, blood glucose levels rising significantly, there is dehydration and electrolyte losses 
by urine, is not stores the fat and protein, even significantly break down protein and fat 
reserves. This dysregulation leads to ketosis and the release of ketone bodies in blood. It is 
unethical not treated animals with glycemia above 25 mM/L. Therefore, certain authors rejected 
animals from experiment with glycemia above 25 mM/L (Matteucci & Giampietro, 2008). 
Similarly, non-treatment of significant hypoglycemia in the initial phase of alloxan diabetes 
is unethical. Some authors reported that animals are treated by glucose solution to alleviate 
complications and death due to hypoglycemia during the first 6 hours after administration 
of alloxan (de Carvalho et al., 2008). 
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Induction of diabetes after administration of diabetogenic substances is confirmed by the 
determination of glucose in blood. After blood collection are blood cells separated within 
one hour with the addition of glycolytic inhibitors. Glucose is then determined in plasma 
by using of standard enzymatic methods  (Sacks et al., 2002). The concentration of glucose 
in plasma is 11% higher than in whole blood and glucose concentration in heparinized 
plasma may be 5% lower than in serum. Glucose concentrations during the oral glucose 
tolerance test in capillary blood are higher (about 20–25%) than in venous blood. 
Variation coefficient for glucose in plasma is 2.2%. Transmissible glucometers have a 
much lower sensitivity than the above coefficient of variation. There are similar 
differences between values measured by different glucometers. American Diabetes 
Association has built a development goal for blood glucose monitors with analytical 
deviations 5%. The diagnosis of diabetes in humans is based on the following criteria 
(ECDCDM, 2003): 
 symptoms of diabetes and casual glycemia above 11.1 mM/L; 
 fasting glycemia (FPG, Fasting Plasma Glucose) 7.0 mM/L; 
 glycemia after glucose load increases over 2 h 11.1 mM/L. 
These values can be confirmed the next day by re-examination. It must be noted that these 
criteria are applicable if the rules for determining the glucose levels are sufficiently accurate 
and sensitive beyond the range of between 7 and 11.1 mM/L. 
When using the blood glucose monitors is needed just a drop of blood (less traumatized 
animals), although reproducibility and statistical accuracy is lower (needs more tests). As is 
to harmonize with the principle of the four R?  
Oral glucose tolerance test (oGTT) provides information on ability to cope with the load by 
glucose. In adults, it is used in 3 hours arrangement and applied to 100 g of glucose in the 
diagnosis of gestational diabetes mellitus, compared with 2 hours arrangement and the 
application of 75 g glucose was used to confirm a diagnosis of diabetes (prediabetes) in the 
previous dubious blood glucose levels. In children used 1.75 g glucose/kg of b.w. maximum 
of 75 g glucose. It is a sensitive test for detection of disorders of glucose metabolism, 
especially if fasting blood glucose are in the dubious areas. For its correct implementation is 
necessary to respect a several principles: 
 does not reduce the glucose uptake three days before the test; 
 test should be performed after fasting overnight (10–14 h); 
 25–30% glucose solution is administered orally; 
 glucose levels are measured before and 30, 60 and 120 minutes after administration of 
glucose; 
 during the test do not receive food and water. 
In rats given 25–30% aqueous solution of anhydrous glucose at a dose of 1-10 g/kg of b.w. 
Sampling are quite different before glucose administration and every 30 minutes up to 300 
minutes after glucose administration (Matteucci & Giampietro, 2008).  
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In rats, it would be appropriate to use a similar arrangement of the test than in children with 
a completed at 120 min, in the case of dubious glucose levels at 8–12 mM/L. 
If in rats are found blood glucose levels (between 12–16 mM/L), they can be considered as 
mild diabetic (or as prediabetic condition). Usually they have after a short period increased 
blood glucose above 16 mM/L, rats with glycemia above this level are considered as clearly 
diabetic (Lukačínová et al., 2008).  
In the oGTT in rats and humans is difference in glucose load in terms of 1 kg of body 
weight. These differences are not indicated anything substantial cause. 
Intravenous glucose tolerance test (ivGTT) used to determine of insulin secretion and 
determination of the first phase of insulin response (FPIR, First Phase Insulin Response), 
which is considered a risk factor for T1D in humans (Culina et al., 2011). When studying 
the prevention of T1D showed that 2 h oGTT was sensitive about 6 months before 
diagnosis of diabetes compared with FPIR, which was lower and declined with age. 
Higher sensitivity was achieved using both tests (Barker et al., 2007). Dextrose was 
administered at a dose of 0.5 g/kg (maximum 35 g) intravenously over 3 minutes. Blood 
was taken with the -10, -4, 1, 3, 5, 7 and 10 minutes before and after load with dextrose 
and analyzed for glucose and insulin. FPIR is expressed on the basis of the sum of values -
1 and 3-minute insulin levels.  
In rats, using anhydrous glucose at a dose of 0.001 to 1.0 g/kg of b.w. and blood glucose 
and insulin are evaluated at different time periods typically from -15 min within 30-120 
minutes from the load with glucose. It should be noted that these tests in animals do not 
have such importance and predictive value as in humans (mainly the system of food 
intake and fasting before the test). Deprivation of food in animals from the evening before 
the examination is a powerful stress stimulus (due to their nocturnal activity), which has a 
significant influence on interindividual differences. Of course it is difficult to determine 
what dose of load in humans corresponds to a similar stress in rats, what is the possibility 
of extrapolation of results between these species. Probably there should be a 35 g aliquot 
of the maximum load in humans (but how and when to realize?). We believe that this 
model could be accepted to study of impact assessment of preventive or therapeutically 
active substances. 
Intraperitoneal glucose tolerance test (ipGTT) is not used in humans. In rats, the dose of 
glucose ranging from 0.2 to 2.0 g/kg of b.w. and monitored for three to seven time periods 
from 0 to 60–120 minutes after load of glucose (Matteucci & Giampietro, 2008). It should 
therefore be considered only as an experimental model without real impact for 
extrapolation. This model may be interesting for studies comparing of load by different 
agents as a possible methodological model.  
When studying the problem of diabetes plays an experimental protocol and the 
possibility of extrapolating a very important role. The experimental protocol must 
include a detailed description of the methods of research, in an experiment to be 
included animals suitable for this study and must be chosen a good system of controls, 
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used substances must be best defined and used appropriate methods of statistical 
analysis of results. E.g., in the case of research in herbal medicine has been submitted 
WHO guidelines specifying the some principles of experiment (WHO, 1993). The 
primary aims of non-clinical studies are: (1) determine whether the substance has a 
beneficial effect in terms of herbal medicine (2) characterize the range of pharmacological 
effects, (3) define the chemical characteristics of the pharmacologically active natural 
products and their mechanisms of action. 
Pharmacodynamic and current pharmacological investigations used animal models or 
bioassays which are good models for modeling of human disease. As an experimental 
object (test system) can be used live animals, isolated organs or tissues, blood and its 
components, tissue and cell cultures, and various subcellular structures. A very 
important point is determining the appropriate doses for a given system from 
viewpoints of study of dose-effect relationship and their extrapolation to human (Resjö 
et al., 2008). In all studies must be a negative control (vehicle without active substance) 
and positive control (known drug/substance). The series of examinations should be tests 
to clarify the biological activity of the herbal preparation. For example, plasma insulin 
concentrations in relation to blood glucose, liver glycogen and triglyceride levels may 
help in understanding the absorption and utilization of glucose and the like. 
Toxicological methods include tests of toxicity (topical, systemic and special). Acute 
toxicity tests require a sufficient number of dose levels to determine the lethal dose and 
monitoring should take at least 7–14 days. In chronic tests of toxicity is application 
period lasts from the 2 weeks to 12 months. Particularly difficult are lifelong toxicity 
tests (Lukačínová et al., 2011). When rodents are used it is recommended that each group 
has at least 5–10 animals for both sexes.   
In most animal studies, the experimenters assessed the effect of intervention on the basis of 
the null hypothesis, i.e. assume that the experimental intervention had no effect. Guidelines 
for construction of animal experiments is why strictly rules necessary for adequate control 
by using the smallest number of animals (Festing & Altman, 2002). Randomization and the 
use of blanks are rarer and therefore animal experiments indicate much more positive 
effects of treatment (Perel et al., 2007). Random choice of animals is essential for selection of 
animals to experimental (treated) and control groups (usually all individuals are healthy!) 
and despite does not reflect adequately to human population. Groups are designated by 
researcher and he knew what was that group treated and has been these groups intervened. 
In this area, animal experiments will be necessary to objectify (one divided and treated 
groups, and other these groups evaluated). 
Since safety and efficacy of drugs before clinical examination are tested on animals, there 
are important all efforts to eliminate bias and random errors.  Moreover, animal models 
should be as much as possible related clinical conditions. This is particularly important 
in extrapolation of dose (g/kg, g/m2 of body surface, resp.). Similarly, when comparing in 
drug already in use, in animal experiments should be used of dosage as in humans.  
 
Animal Models for Study of Diabetes Mellitus 247 
5. Conclusion 
The dawn and the subsequent development of experimental medicine in the second half of 
the XIXth century was unimaginable without the use of animals. Nobody cared about their 
fate and suffering – they were sacrificed in the war against diseases and for the development 
of science. The rules of experiment were simple and represented only the needs of the 
experimentator. The discovery of pancreatic diabetes and the subsequent isolation of insulin 
are the best examples of this era. 
The situation changed dramatically in the second half of the XXth century in the development 
of new methods on laboratory analysis, in the development of new preventive and therapeutic 
procedures but especially in the new non-animal and animal models for the study in this area. 
For this analysis shows that are not yet standardized animal experiments even in the study of 
diabetes. These differences can lead to different conclusions regarding the pharmacologically 
active substances used in particular in the prevention but also in treatment of diabetes 
mellitus, e.g., hypoglycemic effect and dose relations in the application of vanadium or 
bioflavonoids (Lukačínová et al., 2008). It will be important to present a unified experimental 
approaches for testing of different substances on animals, both from the aspect of arrangement 
the experiment (control groups, conditions of experiment, statistical evaluation) as well as the 
selection of the studied parameters (markers) for individual type of test (acute, chronic, etc.) or 
the test substance. In this consideration is necessary increased attention to the requirements for 
the application of 4R. In this case, it can be expected the significant reduction in the need for 
experimental animals, does not need to repeat certain experiments only because they were not 
considered some of the basic conditions (often simple parameters such as the weight of the 
animals, water intake, food intake, urine output, etc.). Therefore, further work is needed to 
improve and refine existing guidelines for their specific needs for testing of biologically active 
substances for medical use. Especially at present when more and more come to the forefront of 
evidence-based medicine (Borgerson, 2005) should become a standard working method in 
animal experiments.  
In any case, in the future is expected many new findings from animal models, particularly in 
the pathogenesis of human diseases. The immediate benefit of such experiments was the 
introduction to testing of insulin therapy, as well as testing of other drugs. It is necessary to 
calculate that there can also lead to no thoroughfares of research, and it should be 
remembered the reproducibility and extrapolation of results for the human population. We 
expect the most benefit but in the verification of preventive strategies with various drugs.   
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